牛牛AI助理已提取核心訊息
Moderna, Inc. (MRNA) has reported a transaction involving Chief Legal Officer Shannon Thyme Klinger. The transaction, dated 02/27/2024, involved the direct acquisition of Moderna's common stock. Following the transaction, Klinger holds a total of 7,912 shares of Moderna directly. The nature of the transaction indicates a vested interest in the company's performance by one of its top executives.
Moderna, Inc. (MRNA) has reported a transaction involving Chief Legal Officer Shannon Thyme Klinger. The transaction, dated 02/27/2024, involved the direct acquisition of Moderna's common stock. Following the transaction, Klinger holds a total of 7,912 shares of Moderna directly. The nature of the transaction indicates a vested interest in the company's performance by one of its top executives.
Moderna, Inc.（MRNA）報告了一筆涉及首席法務官香農·泰裏姆·克林格的交易。該交易日期爲2024年2月27日，涉及直接收購Moderna的普通股。交易完成後，克林格直接持有Moderna共7,912股股份。該交易的性質表明，該公司的一位高管對公司的業績具有既得利益。
Moderna, Inc.（MRNA）報告了一筆涉及首席法務官香農·泰裏姆·克林格的交易。該交易日期爲2024年2月27日，涉及直接收購Moderna的普通股。交易完成後，克林格直接持有Moderna共7,912股股份。該交易的性質表明，該公司的一位高管對公司的業績具有既得利益。
有用
沒用